Compugen Posts $0.08 Q1 Loss on $2.18M Revenue, Advances 11 Trials
CGEN•Compugen reported Q1 2026 loss per share of $0.08 on $2.18 million revenue, missing estimates and down from $2.28 million a year earlier. It is enrolling COM701 ovarian cancer trial patients, advancing 11 late-stage rilvegostomig trials with AstraZeneca and has cash runway into 2029 with 6.56 current ratio.
1. Q1 Financial Results
Compugen reported Q1 2026 EPS loss of $0.08 versus a $0.07 consensus estimate, matching last year’s per-share loss, and posted revenue of $2.18 million, down from $2.28 million a year earlier, missing analysts’ revenue forecasts.
2. Clinical Trial Advancement
The company is enrolling patients in its COM701 ovarian cancer trial and advancing its AstraZeneca partnership, currently conducting 11 late-stage rilvegostomig studies with new data expected soon, highlighting momentum in its oncology pipeline.
3. Balance Sheet Strength
With sufficient cash to fund operations into 2029, a debt-to-equity ratio of 0.03 and a current ratio of 6.56, Compugen’s balance sheet remains robust to support ongoing clinical development.
Related News
Skyline Builders Group Holding acquires two highly prospective gold and silver mineral properties in Nevada
Paramount Skydance Corporation Announces Extension Of Expiration Dates Of Previously Announced Exchange Offers And Tender Offers
